网站综合信息 telik.org
- 标题:
- Telik, Inc.
- 关键字:
- 描述:
- 域名信息
- 服务器空间
- IP:205.178.189.131 同IP网站1794个 详情
地址:美国 弗吉尼亚州赫恩登镇Network Solutions公司
- 备案信息
- 备案号:
域名流量Alexa排名
域名注册Whois信息
telik.org
获取时间: 2013年08月06日 05:02:34
WHOIS LIMIT EXCEEDED - SEE WWW.PIR.ORG/WHOIS FOR DETAILS
网站头文件(HTTP Header)
HTTP/1.1 301 永久重定向 服务器:Sun-ONE-Web-Server/6.1 访问时间:2013年08月06日 04:52:01 文件大小:122 类型:text/html 目标网址:http://www.telik.com 连接:关闭 HTTP/1.1 200 OK 访问时间:2013年08月06日 04:52:01 服务器:Apache/2.2.22 (Unix) FrontPage/5.0.2.2635 修改日期:2013年05月14日 04:12:09 网页标记:"27a2995-35f5-4dc9f21a77e49" 接受单位:字节 文件大小:13813 Keep-Alive: timeout=3, max=200 连接:Keep-Alive 类型:text/html 页面编码:windows-1252
同IP网站(同服务器)
网站首页快照(纯文字版)
抓取时间:2013年08月06日 05:02:34
网址:http://telik.org/
标题:Telik, Inc.
关键字:
描述:
主体:
网址:http://telik.org/
标题:Telik, Inc.
关键字:
描述:
主体:
Telik, Inc. (Nasdaq: TELK) is a biopharmaceutical company dedicated to discovering, developing and commercializing novel small molecule drugs to treat cancer and other serious diseases. One development candidate is TELINTRA® (TLK199) which is currently in Phase 2 clinical development for myelodysplastic syndrome, and severe chronic idiopathic neutropenia. TELINTRA® is also being evaluated for the treatment of additional blood disorders. Another product candidate, TELCYTA® (TLK286), is a cancer cell-activated chemotherapeutic that has shown clinical activity in Phase 2 and Phase 3 clinical trials in advanced ovarian cancer, non-small cell lung cancer, colon cancer and breast cancer. These product candidates, and the other candidates in our pipeline, were discovered using our proprietary technology, TRAP®, which enables the rapid and efficient discovery of small molecule drug candidates. Investor Info 2012 Annual Report 2013 Proxy Statement Latest News May 10, 2013 Telik Announces First Quarter 2013 Financial Results March 15, 2013 Telik Announces Fourth Quarter and 2012 Year End Financial Results and 2013 Financial Guidance January 22, 2013 Telik Announces Preliminary Agreement on Design of Phase 3 Registration Trial of Telintra® in Low to Intermediate-1 Risk Myelodysplastic Syndrome January 11, 2013 Telik Announces Orphan Designation of Telintra® for Treatment of Myelodysplastic Syndrome December 12, 2012 Telik Announces Telintra® Clinical Publication at the 54th Annual Meeting of the American Society of Hematology Home | About Telik | Research | Clinical Trials | Investor Info | Careers | Contact | Sitemap | Legal Notice 2100 Geng Road, Suite 102, Palo Alto, CA 94303Tel 650-845-7700Fax 650-845-7800 ©2010 Telik, Inc. All rights reserved.